PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality.
• Immune checkpoint therapy shows promise but has limited patient response.
• Understanding CRC immunosuppression mechanisms is crucial for improving treatments.

Purpose of the Study:

• To investigate the role of PIPKIγ in colorectal cancer immunosuppression.
• To identify mechanisms driving tumor-associated macrophage infiltration in CRC.
• To explore PIPKIγ as a potential therapeutic target for CRC.

Main Methods:

• Analysis of The Cancer Genome Atlas (TCGA) datasets.
• Loss-of-function studies involving PIPKIγ silencing.
• Assessment of CCL2 expression and macrophage chemotaxis.
• Investigation of the PI3K-Akt-mTOR and STAT3 signaling pathways.

Main Results:

• High PIPKIγ expression correlates with increased tumor-associated macrophage infiltration in CRC.
• Silencing PIPKIγ significantly reduces CCL2 expression and macrophage chemotaxis.
• PIPKIγ activates the PI3K-Akt-mTOR pathway, leading to STAT3 phosphorylation and CCL2 transcription.
• PIPKIγ enhances tumor-associated macrophage recruitment.

Conclusions:

• The PIPKIγ signaling pathway is a key mediator of colorectal cancer immunosuppression.
• PIPKIγ facilitates tumor-associated macrophage recruitment through the PI3K-Akt-mTOR/STAT3 axis.
• Targeting the PIPKIγ pathway presents a novel therapeutic strategy for colorectal cancer.